7171 FREDERICK BANTING, SAINT-LAURENT, A8
Repare Therapeutics Announces Phase 1 Trial Data for RP-1664
Provides Business Update and Reports Second Quarter 2025 Financial Results
Enters Exclusive Worldwide Licensing Agreement for Lunresertib
Changes in Board, Management or Compensation
Shareholder votes
Amended material disclosure
Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results
Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement